OPEN LABEL STUDY OF ALPRAZOLAM IN SEVERELY DEPRESSED INPATIENTS

Abstract

Severely depressed inpatients received alprazolam in doses adjustable from 1.5 mg-5.0 mg/day. Half of the 26 patients improved with .gtoreq. 50% reduction on the Hamilton Psychiatric Rating Scale for Depression or had a final total score of 8 or less. Patient response to treatment over the 6-wk study was associated with marked improvement during the 1st wk.